NASDAQ · NVS
Healthcare · Drug Manufacturers - General
$160.79
Down-$0.31 (-0.19%)
Updated Oct 31, 2026, 5:40 PM
SID Score
7.4/10
Composite research score
Smart Money
43/100
Neutral
Price performance · NVS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
NVS closed at $160.79 after 21 trading sessions, up 14.04% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $162.53 | $164.055 | $160.40 | $160.79 | 3.15M |
| Oct 29, 2026 | $160.68 | $162.19 | $159.91 | $161.10 | 2.24M |
| Oct 28, 2026 | $154.86 | $157.41 | $154.11 | $156.08 | 1.95M |
| Oct 27, 2026 | $154.15 | $156.985 | $154.13 | $156.86 | 3.73M |
| Oct 26, 2026 | $153.525 | $154.24 | $152.02 | $153.81 | 2.82M |
| Oct 23, 2026 | $156.08 | $156.08 | $149.17 | $151.12 | 4.36M |
| Oct 22, 2026 | $154.90 | $157.10 | $154.38 | $156.27 | 2.08M |
| Oct 21, 2026 | $153.12 | $154.12 | $152.93 | $153.93 | 1.02M |
| Oct 20, 2026 | $152.15 | $153.68 | $151.95 | $153.64 | 1.36M |
| Oct 19, 2026 | $150.22 | $150.90 | $149.625 | $150.20 | 1.87M |
| Oct 16, 2026 | $150.65 | $151.735 | $150.23 | $150.62 | 1.73M |
| Oct 15, 2026 | $150.32 | $151.83 | $149.635 | $150.38 | 2.09M |
| Oct 14, 2026 | $144.35 | $147.16 | $144.17 | $146.88 | 1.65M |
| Oct 13, 2026 | $145.18 | $145.24 | $142.31 | $142.41 | 1.84M |
| Oct 12, 2026 | $143.84 | $144.02 | $143.115 | $143.84 | 1.15M |
| Oct 9, 2026 | $142.92 | $143.96 | $142.80 | $143.75 | 1.9M |
| Oct 8, 2026 | $142.77 | $143.29 | $140.68 | $143.11 | 1.53M |
| Oct 7, 2026 | $143.12 | $144.275 | $142.545 | $143.28 | 1.85M |
| Oct 6, 2026 | $141.32 | $141.39 | $139.665 | $140.79 | 1.57M |
| Oct 5, 2026 | $141.02 | $141.02 | $139.31 | $140.93 | 1.33M |
| Oct 2, 2026 | $141.46 | $141.57 | $139.95 | $141.00 | 2.25M |
The latest Smart Investors Daily articles mentioning NVS.
Company
Market Activity
Research & News
NVS research
Company profile and research snapshot.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | ROTHSCHILD & CO REDBURN | Sell | — |
| Sep 23, 2026 | LANDESBANK BADEN-WUERTTEMBERG | Hold | — |
| Sep 21, 2026 | BERENBERG | Hold | — |
| Sep 18, 2026 | JEFFERIES | Hold | — |
| Sep 17, 2026 | BAADER EUROPE / ALPHAVALUE | Buy | — |
Generated Oct 31, 2026, 5:20 PM
Novartis shares slipped 0.19% today amid a complex earnings season narrative marked by conflicting analyst recommendations and competitive pressures from rival pharmaceuticals. While the company's Q3 2026 results confirmed a rebound story, a notable Deutsche Bank downgrade to Sell offset positive developments in gene therapy markets where Novartis is gaining traction.
Bottom line: Novartis presents a mixed investment picture with solid operational fundamentals and compelling long-term growth opportunities in gene therapy, tempered by analyst disagreement and competitive headwinds in core markets. Investors should monitor upcoming pipeline developments and quarterly cash flow trends, while the recent Deutsche Bank downgrade suggests waiting for more compelling entry points or clarity on valuation.
SeekingAlpha · Oct 31, 2026
Novartis is rated Hold, with a 12-month price target of $141.81, implying a 12.0% downside from the current share price. Read more on NVS stock here.
Yahoo · Oct 30, 2026
Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Yahoo · Oct 30, 2026
Players: Pfizer, Novartis, Bayer, Astellas and Sarepta. Profile: next-gen AAV delivery, including engineered capsids, targeting, safety and scalable manufacturing.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global next-generation adeno-associated virus (AAV) gene therapy delivery market is experiencing rapid expansion as biotechnology companies, ph
Yahoo · Oct 30, 2026
Boost ROI via targeted siRNA delivery, personalized therapies, pipeline-expanding acquisitions, and focus on renal, rare, neurological and oncology indications.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Gene Silencing Therapeutics Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global gene silencing therapeutics market is experiencing rapid growth, supported by advances in molecular medicine, RNA-based therapies and targeted treatment strategies. The market is
Interpretive context generated from the platform’s current data sources.
Novartis AG shares have demonstrated strong upward momentum across multiple timeframes, per SID market data. The stock trades at $160.79, reflecting a 13.0% gain over the past month and a 24.75% advance over the trailing twelve months. On a three-month basis, NVS has returned 3.17%, indicating that much of the recent rally has been concentrated in the last four weeks. The stock currently trades well above both its 50-day moving average of $148.31 and its 200-day moving average of $151.64, confirming a sustained bullish trend. However, the 14-day relative strength index registers at 76.4, placing the stock in overbought territory above the conventional 70 threshold. Novartis carries a beta of 0.438, according to Massive/Polygon data, underscoring its defensive profile relative to the broader market. Average daily trading volume stands at approximately 1.65 million shares.
Novartis AG commands a market capitalization of approximately $259.0 billion, positioning it among the largest healthcare companies globally, per SID market data. The stock trades at a price-to-earnings ratio of 18.18, which is broadly in line with large-cap pharmaceutical peers. The price-to-book ratio stands at 5.90, according to SEC filings, reflecting a meaningful premium to book value that suggests the market is pricing in substantial intangible asset value including the company's pharmaceutical pipeline. The PEG ratio registers at negative 0.79, indicating that consensus growth estimates currently factor in an earnings contraction over the forecast period, which tempers the valuation picture. On the income return front, Novartis offers a dividend yield of approximately 3.31%, providing a significant income component for shareholders. This yield remains attractive relative to the broader healthcare sector, reinforcing the stock's appeal among income-oriented investors seeking defensive exposure.
The composite smart money score for Novartis AG stands at 43 out of 100, generating a neutral signal according to SID market data. Institutional positioning represents the strongest component, scoring 21.0 out of 25, which indicates that large asset managers maintain robust allocations to the stock. Insider activity scores 12.5 out of 25, per SEC Form 4 filings, reflecting a moderate level of transactions by company executives and directors without a decisive directional bias. Dark pool activity registers at 8.5 out of 25, suggesting below-average volume flowing through alternative trading systems, which may indicate limited urgency among large block traders. Congressional trading activity is notably minimal at 0.8 out of 25, per 13F institutional filings, showing virtually no disclosed positions by members of Congress. The divergence between strong institutional conviction and weaker dark pool and congressional signals creates a mixed overall picture, with no clear directional consensus among sophisticated market participants at current price levels.
Novartis AG has established a pattern of outperformance relative to consensus expectations, according to company earnings reports. In the most recent reported quarter, the company posted earnings of $2.46 per share against analyst estimates of $2.24, delivering a positive surprise of $0.22. The prior quarter similarly exceeded expectations, with actual earnings of $2.41 per share versus estimates of $2.16, representing a $0.25 beat. These consecutive upside surprises reflect strong operational execution and effective cost management. Looking ahead, analysts project earnings of $2.13 per share for the upcoming quarter with results expected on July 16, 2026, followed by an estimate of $2.10 per share for the subsequent period due May 1, 2026, per analyst estimates. The sequential moderation in forward estimates suggests the market anticipates a slight near-term earnings deceleration. Investors will closely monitor whether Novartis can sustain its trend of surpassing consensus forecasts.
Wall Street coverage of Novartis AG reflects a divided outlook, per SID consensus data. In the most recent round of analyst activity, Rothschild & Co Redburn reiterated a Sell rating on September 23, 2026, maintaining a bearish stance on the stock. On the same date, Landesbank Baden-Wuerttemberg reaffirmed a Hold rating. Berenberg and Jefferies also maintained Hold positions on September 21 and September 18, respectively, according to Wall Street analyst reports. On the bullish side, Baader Europe/AlphaValue reiterated a Buy rating on September 17, 2026. Among the five most recent ratings, three analysts recommend Hold, one rates the stock a Buy, and one maintains a Sell, indicating that the consensus leans toward a neutral-to-cautious posture. Notably, none of the recent actions involved rating changes — all five were reiterations of prior positions — suggesting that the stock's 13.0% monthly rally has not yet prompted analysts to meaningfully revise their fundamental views on Novartis.
The latest Smart Investors Daily articles mentioning NVS.
